In a filing, Keros Therapeutics Inc. revealed its Chief Financial Officer Regnante Keith unloaded Company’s shares for reported $0.91 million on Jun 09. In the deal valued at $45.42 per share,20,000 shares were sold. As a result of this transaction, Regnante Keith now holds 0 shares worth roughly $ 0.0.
Then, Regnante Keith sold 20,000 shares, generating $955,872 in total proceeds. Upon selling the shares at $47.79, the Chief Financial Officer now owns 0 shares.
Wedbush initiated its Keros Therapeutics Inc. [KROS] rating to an Outperform in a research note published on Friday, July 31, 2023; the price target was $86. PT values the company’s stock at a premium of 57.86 to its Friday closing price.
Price Performance Review of KROS
On Friday, Keros Therapeutics Inc. [NASDAQ:KROS] saw its stock jump 3.22% to $36.24. On the same session, the stock had its day’s lowest price of $35.0875, but rose to a high of $36.28. Over the last five days, the stock has gained 0.03%. Keros Therapeutics Inc. shares have fallen nearly -24.53% since the year began. Nevertheless, the stocks have risen 2.46% over the past one year. While a 52-week high of $59.96 was reached on 03/03/23, a 52-week low of $33.09 was recorded on 08/17/23. SMA at 50 days reached $38.83, while 200 days put it at $45.45. A total of 0.15 million shares were traded, compared to the trading of 0.2 million shares in the previous session.
Levels Of Support And Resistance For KROS Stock
The 24-hour chart illustrates a support level at 35.46, which if violated will result in even more drops to 34.68. On the upside, there is a resistance level at 36.65. A further resistance level may holdings at 37.06. The Relative Strength Index (RSI) on the 14-day chart is 46.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.06%. Stochastics %K at 59.94% indicates the stock is a holding.
How much short interest is there in Keros Therapeutics Inc.?
A steep rise in short interest was recorded in Keros Therapeutics Inc. stocks on Aug 14, 2023, growing by 0.16 million shares to a total of 1.13 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.97 million shares. There was a rise of 13.86%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.02% of the overall stock float, the days-to-cover ratio (short ratio) rose to 6.65.
Keros Therapeutics Inc. [KROS] – Who Are The Largest Shareholders?
In filings from Fidelity Management & Research Co, it is revealed that the company now owns 4,028,136 shares, or roughly 13.62% of the outstanding KROS shares. In other words, the investor’s shares have risen by 4,050 from its previous 13-F filing of 4024086.0. Additionally, Alkeon Capital Management LLC decreased -0.09% of its stake after which the total value it holdings stand at $70,212,741, while BlackRock Fund Advisors added 11.20% of its stake to hold $60.96 million in the firm. Over the last quarter, T. Rowe Price Associates, Inc. purchased 116,897 shares of Keros Therapeutics Inc., while Braidwell LP bought 1,143,865 shares. At present, The Vanguard Group, Inc. is holding 1,125,958 shares valued at $47.16 million. SSgA Funds Management, Inc. owned 1,015,903 shares of the company at the time of its most recent 13F filing, worth $42.55 million.
According to FactSet, Keros Therapeutics Inc.’s share price will average $90.25 in the next year, based on opinions of analysts polled by the firm. This is up nearly 164.88 percent from its previous closing price of $35.11. Analysts expect Keros Therapeutics Inc. stock to reach the higher price of $110.00, while the lowest price estimate is $66.00. However, 9 analysts have rated KROS stock as a Buy in their predictions for 2023.